news
Aesica adds development capability with new purpose built facility
20 April 2017 | By Aesica Pharmaceuticals
Product life cycle services expanded, including for high potent and controlled drugs...
List view / Grid view
Formulation
whitepaper
Application note: Testing and validation of various antacids for class 1 and 2A elemental impurities
In this paper, PerkinElmer present data to illustrate the successful validation of the NexION® 2000 ICP Mass Spectrometer for the determination of Class 1 and 2A elemental impurities in antacids according to USP General Chapter ...
article
Issue #2 2017 – Digital version
Read the free-to-view digital version of the latest issue of European Pharmaceutical Review...
news
Study finds genetic basis for drug response in childhood absence epilepsy
13 April 2017 | By Niamh Marriott, Junior Editor
A new childhood absence epilepsy study has identified genes that show individual reactions and could be used as a precision medicine approach...
whitepaper
Whitepaper: Insight-Driven Formulations Development
This whitepaper describes how deploying such a platform can provide end-to-end visibility across Pre-formulations and Formulations Development and expedite the identification and progression of safe, efficacious formulations...
news
EPSRC commits £15 million for formulation manufacturing research
New research projects that aim to improve the complex formulation processes used to manufacture products such as toothpastes, inhalers, films that coat solar cells and pharmaceuticals are to receive significant funding from the Engineering and Physical Sciences Research Council (EPSRC).
news
Global trade bodies issue guidance on biosimilar switching
9 March 2017 | By European Pharmaceutical Review
EFPIA, EBE and IFPMA issue joint guidance for prescribers on switching between original reference biologics and biosimilars...
article
Improving the consistency of MDI drug delivery
A defining characteristic of inhaled drug delivery is variability in the dose received by the patient, as a result of physiology, for example, or the technique applied during use. This variability directly affects clinical outcomes so reducing it to a minimum is an important goal for the industry...
article
Understanding the effect of API changes in pharmaceutical processing
For the pharmaceutical scientist, the journey of an active molecule from the end of its synthetic pathway and crystallisation to its ultimate site of action is a fascinating one, and one that is necessary to understand...
article
Issue #1 2017 – Digital version
Read the free-to-view digital version of the latest issue of European Pharmaceutical Review...
article
Formulation Development & Drug Delivery In-Depth Focus 2017
Understanding the effect of API changes in pharmaceutical processing; Improving the consistency of MDI drug delivery; and Expert Views with DDF Summit and Eurofins Lancaster Laboratories...
article
Biosimilars create opportunities for sustainable cancer care
22 February 2017 | By Professor Josep Tabernero, Chair of the ESMO Cancer Medicines Working Group
Dr Josep Tabernero explains the benefits of biosimilars, showing how they can create sustainable, safe and affordable access to medicine globally...
article
Quality by Design for generic products: opportunities and challenges
The first part of an in-depth article on Quality by Design (QbD), published in European Pharmaceutical Review in December 2016, focused on designing quality in to a pharmaceutical drug product by considering dosage form design, and understanding the importance of active pharmaceutical ingredients’ (APIs’) and excipients’ properties.
webinar
NIR Spectroscopy for Assessing Blend Uniformity in the Pharmaceutical Industry
21 February 2017 | By Viavi Solutions Inc.
This webinar presented the use of MicroNIR PAT for monitoring the endpoint of powder blending operations and discussed challenges that need to be addressed for successful implementation...
whitepaper
Whitepaper: Accelerating development of enabled formulations for poorly soluble drugs
In this whitepaper, Quotient Clinical discuss poorly soluble drugs and how they have developed an innovative approach to identify and overcome these solubility challenges...
